Toremfine 20 - Dragon Pharma

Toremifene, developed in the 1980s, is a SERM targeting metastatic breast cancer in postmenopausal women. It binds to receptors in breast tissue, stopping tumor growth. Primarily available as toremifene citrate, clinical trials confirm its effectiveness is comparable to tamoxifen. Has also been researched for other cancers, including ovarian and endometrial carcinoma. Studies on animals show reduced tumor occurrence, particularly in mammary glands, with indications of lowered cardiovascular risks in human trials.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Toremfine 20 by Dragon Pharma, consult with your doctor or healthcare professional.